These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Update on the evaluation and treatment of osteogenesis imperfecta. Harrington J; Sochett E; Howard A Pediatr Clin North Am; 2014 Dec; 61(6):1243-57. PubMed ID: 25439022 [TBL] [Abstract][Full Text] [Related]
5. Severe osteogenesis imperfecta Type-III and its challenging treatment in newborn and preschool children. A systematic review. Sinikumpu JJ; Ojaniemi M; Lehenkari P; Serlo W Injury; 2015 Aug; 46(8):1440-6. PubMed ID: 25943292 [TBL] [Abstract][Full Text] [Related]
6. The management of osteogenesis imperfecta in adults: state of the art. Lafage-Proust MH; Courtois I Joint Bone Spine; 2019 Oct; 86(5):589-593. PubMed ID: 30742929 [TBL] [Abstract][Full Text] [Related]
7. Intravenous pamidronate in osteogenesis imperfecta type VII. Cheung MS; Glorieux FH; Rauch F Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231 [TBL] [Abstract][Full Text] [Related]
8. Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta. Liu W; Lee B; Nagamani SCS; Nicol L; Rauch F; Rush ET; Sutton VR; Orwoll E J Clin Endocrinol Metab; 2023 Jun; 108(7):1787-1796. PubMed ID: 36658750 [TBL] [Abstract][Full Text] [Related]
9. Advances in the Classification and Treatment of Osteogenesis Imperfecta. Thomas IH; DiMeglio LA Curr Osteoporos Rep; 2016 Feb; 14(1):1-9. PubMed ID: 26861807 [TBL] [Abstract][Full Text] [Related]
10. Osteogenesis imperfecta: from diagnosis and multidisciplinary treatment to future perspectives. Bregou Bourgeois A; Aubry-Rozier B; Bonafé L; Laurent-Applegate L; Pioletti DP; Zambelli PY Swiss Med Wkly; 2016; 146():w14322. PubMed ID: 27346233 [TBL] [Abstract][Full Text] [Related]
11. Novel mutations in FKBP10 in Chinese patients with osteogenesis imperfecta and their treatment with zoledronic acid. Xu XJ; Lv F; Liu Y; Wang JY; Ma DD; Asan ; Wang JW; Song LJ; Jiang Y; Wang O; Xia WB; Xing XP; Li M J Hum Genet; 2017 Feb; 62(2):205-211. PubMed ID: 27762305 [TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up in osteogenesis imperfecta type VI. Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307 [TBL] [Abstract][Full Text] [Related]
14. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate. Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348 [TBL] [Abstract][Full Text] [Related]
15. Filling the gaps: osteogenesis imperfecta. Graul AI Drug News Perspect; 2005; 18(6):400-1. PubMed ID: 16247517 [No Abstract] [Full Text] [Related]
18. New trends in the treatment of osteogenesis imperfecta type III - own experience. Jakubowska-Pietkiewicz E; Chlebna-Sokół D Ortop Traumatol Rehabil; 2008; 10(6):593-601. PubMed ID: 19153548 [TBL] [Abstract][Full Text] [Related]
19. Growth of infants with osteogenesis imperfecta treated with bisphosphonate. Hasegawa K; Inoue M; Seino Y; Morishima T; Tanaka H Pediatr Int; 2009 Feb; 51(1):54-8. PubMed ID: 19371278 [TBL] [Abstract][Full Text] [Related]